Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Francisco Bautista und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, Hospital Universitario Niño Jesús, Madrid, Spain. Hauptthemen laut MEDLINE: Neoplasms, Drug Development. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE The aim of the Innovative Therapies for Children with Cancer (ITCC) consortium is to improve access to novel therapies for children and adolescents with cancer. The evolution of the ITCC clinical trial portfolio since 2003 was reviewed. METHODS All ITCC-labeled phase I/II trials opened between January 1, 2003 and February 3, 2018 were analyzed in two periods (2003-2010 and 2011-2018), and data were extracted from the ITCC database, regulatory agencies' registries, and publications. RESULTS Sixty-one trials (62% industry-sponsored) enrolled 3,198 patients. The number of trials in the second period increased by almost 300% (16 v 45). All biomarker-driven trials (n = 14) were conducted in the second period. The use of rolling six and model-based designs increased (1 of 9, 11% v 21 of 31, 68%), and that of 3 + 3 designs decreased (5 of 9, 55% v 5 of 31, 16%; P = .014). The proportion of studies evaluating chemotherapeutics only decreased (5 of 16, 31% v 4 of 45, 9%), the proportion of single-agent targeted therapies did not change (9 of 16, 56.2% v 24 of 45, 53.3%), the proportion of combination targeted therapies trials increased (2 of 16, 12%, v 17 of 45, 38%), the proportion of randomized phase II trials increased (1 of 7, 14% v 8 of 14, 57%). More trials were part of a pediatric investigation plan in the second period (4 of 16, 25% v 21 of 45, 46%). The median time for Ethics Committees' approvals was 1.7 times longer for academic compared with industry-sponsored trials. CONCLUSION This study reports a shift in the paradigm of early drug development for childhood cancers, with more biologically relevant targets evaluated in biomarker-driven trials or in combination with other therapies and with more model-based or randomized designs and a greater focus on fulfilling regulatory requirements. Improvement of trial setup and recruitment could increase the number of patients benefiting from novel agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology and Oncology, Hospital Universitario Niño Jesús, Madrid, Spain.
- Princess Máxima Center, Utrecht, the Netherlands.
- Division of Pediatric Hematology and Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute, INCLIVA, Valencia, Spain.
- Pediatric and Adolescent Oncology Department, Gustave Roussy Cancer Campus, INSERM U1015, Université Paris-Saclay, Villejuif, France.
- Institut Curie & Université Versailles St Quentin & INSERM U900 STAMPM, Paris, France.
- Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
ORCID-Profile: Francisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, Alba Rubio-San-Simón, Xavier Paoletti, C Michel Zwaan, Michela Casanova, Fernando Carceller, Francois Doz, Gilles Vassal, Andrew D J Pearson, Pamela Kearns, Lucas Moreno
Zitieren
APA
Bautista, F., Verdú-Amorós, J., Geoerger, B., Rubio-San-Simón, A., Paoletti, X., Zwaan, C. M., Casanova, M., Marshall, L. V., Carceller, F., Doz, F., Lecinse, C., Vassal, G., Pearson, A. D. J., Kearns, P., Moreno, L., & Innovative Therapies For Children With Cancer Consortium (2024). Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01237
Vancouver
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, et al. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01237
BibTeX
@article{Bautista2024,
author = {Bautista, Francisco and Verdú-Amorós, Jaime and Geoerger, Birgit and Rubio-San-Simón, Alba and Paoletti, Xavier and Zwaan, C Michel and Casanova, Michela and Marshall, Lynley V and Carceller, Fernando and Doz, Francois and Lecinse, Carole and Vassal, Gilles and Pearson, Andrew D J and Kearns, Pamela and Moreno, Lucas and Innovative Therapies For Children With Cancer Consortium, Innovative Therapies For Children With Cancer Consortium},
title = {Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01237}
}
EUVIMED